Lexeo's PKP2 gene therapy shows arrhythmia drop as company maps faster regulatory route
Lexeo says early LX2020 results and its reading of FDA's stance could shorten the path to market, though the agency has not confirmed that position.
Lexeo Therapeutics is putting a faster regulatory route at the centre of the case for LX2020, its gene therapy for heart disease caused by PKP2 mutations. The company said on 16 November 2026, in an investor presentation, that the US Food and Drug Administration is receptive to using a measure of arrhythmia as the main endpoint for a possible conditional approval. The material available to CompePharma contains no revenue projections, pricing or deal terms, so the commercial implications remain unquantified.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Company's press release (SEC filing): Lexeo Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.